Thrombin is the pivotal enzyme in the biochemistry of secondary hemostasis crucial to
maintaining homeostasis of hemostasis. In contrast to routine coagulation tests (PT or aPTT) …

Early recognition of coagulopathy is necessary for its prompt correction and successful
management. Novel approaches, such as point-of-care testing (POC) and administration of …

Background In the AVERROES study, apixaban, a novel factor Xa inhibitor, reduced the risk
of stroke or systemic embolism in patients with atrial fibrillation who were at high risk of …

Aims Patients with atrial fibrillation (AF) are at increased risk of stroke. Betrixaban is a novel
oral factor Xa inhibitor administered once daily, mostly excreted unchanged in the bile and …

The current document commissioned by the Society for Cardiovascular Angiography and
Interventions (SCAI) and endorsed by the American College of Cardiology, the American …

Anticoagulation carries a tremendous therapeutic advantage in reducing morbidity and
mortality with venous thromboembolism and atrial fibrillation. For over six decades …

Abstract Human factor Xa (FXa) is a serine protease of the common coagulation pathway.
FXa is known to activate prothrombin to thrombin, which eventually leads to the formation of …

Background The optimal dosing strategy of four-factor prothrombin complex concentrate (4F-
PCC) to treat oral factor Xa (FXa) inhibitor-associated bleeding has not been established …

Direct oral anticoagulant drugs (DOACs) interfere with the coagulation process, thus
improving patient care for those who require anticoagulant treatment. This study presents a …

Treatment of bleeding and thrombotic disorders is highly standardized and based on
evidence-based medicine guidelines. These evidence-based treatment schemes are well …